Randomized, phase II study of weekly paclitaxel plus carboplatin versus biweekly paclitaxel plus carboplatin for patients with previously untreated advanced non-small-cell lung cancer

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2019
INTERVENTION: A group: Biweekly treatment TXL 135mg/m2 day1, 15+CBDCA(AUC=3)day1, 15 every 28 days for 4 cycles B group: Weekly treatment TXL 90mg/m2 day1, 8, 15 + CBDCA(AUC=6) day1 every 28 days for 4 cycles CONDITION: advanced non‐small cell lung cancer (NSCLC) PRIMARY OUTCOME: Objective Response Rate (ORR) SECONDARY OUTCOME: Safety, Progression Free Survival, Overall Survival INCLUSION CRITERIA:
Epistemonikos ID: b6944b0be00f1ce3cbf9f6fa54e6a6f906f98bcf
First added on: Aug 24, 2024